Jisun Ban
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jisun Ban has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Andrew T. Lucas
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
1 shared publication - Joseph A. Piscatelli
UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA
1 shared publication - William C. Zamboni
University of North Carolina at Chapel Hill 4 Lineberger Comprehensive Cancer Center, School of Medicine Chapel Hill, North Carolina
1 shared publication
Latest Publications
- Open Access
- 17 January 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (1) , 114
Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems
Major developments in nanomedicines, such as nanoparticles (NPs), nanosomes, and conjugates, have revolutionized drug delivery capabilities over the past four decades. Although nanocarrier agents provide numerous advantages (e.g., greater solubility and duration of systemic exposure) compared to their small-molecule counterparts, there is considerable inter-patient variability seen in the systemic disposition, tumor delivery and overall pharmacological effects (i.e., anti-tumor efficacy and unwanted toxicity) of NP agents. This review aims to provide a summary of fundamental factors that affect the disposition of NPs in the treatment of cancer and why they should be evaluated during preclinical and clinical development. Furthermore, this chapter will highlight some of the translational challenges associated with elements of NPs and how these issues can only be addressed by detailed and novel pharmacology studies.
- 17 January 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (1) , 114
Open AccessComplex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems
Major developments in nanomedicines, such as nanoparticles (NPs), nanosomes, and conjugates, have revolutionized drug delivery capabilities over the past four decades. Although nanocarrier agents provide numerous advantages (e.g., greater solubility and duration of systemic exposure) compared to their small-molecule counterparts, there is considerable inter-patient variability seen in the systemic disposition, tumor delivery and overall pharmacological effects (i.e., anti-tumor efficacy and unwanted toxicity) of NP agents. This review aims to provide a summary of fundamental factors that affect the disposition of NPs in the treatment of cancer and why they should be evaluated during preclinical and clinical development. Furthermore, this chapter will highlight some of the translational challenges associated with elements of NPs and how these issues can only be addressed by detailed and novel pharmacology studies.